المؤلفون: AlRuthia Y; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almadi M; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.; Division of Gastroenterology, The McGill University Health Center, Montreal General Hospital, McGill University, Montreal, Canada., Aljebreen A; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia., Azzam N; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia., Alsharif W; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alrasheed H; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almuaythir G; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Saeed M; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia., HajkhderMullaissa B; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia., Alharbi O; Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.

المصدر: Journal of medical economics [J Med Econ] 2020 Oct; Vol. 23 (10), pp. 1102-1110. Date of Electronic Publication: 2020 Jul 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Inflammatory Agents/*economics , Anti-Inflammatory Agents/*therapeutic use , Biological Products/*economics , Biological Products/*therapeutic use , Inflammatory Bowel Diseases/*drug therapy, Adalimumab/economics ; Adalimumab/therapeutic use ; Adult ; Colitis, Ulcerative/drug therapy ; Cost-Benefit Analysis ; Crohn Disease/drug therapy ; Female ; Health Expenditures/statistics & numerical data ; Health Resources/economics ; Health Resources/statistics & numerical data ; Health Services/economics ; Health Services/statistics & numerical data ; Humans ; Infliximab/economics ; Infliximab/therapeutic use ; Male ; Middle Aged ; Models, Econometric ; Quality of Life ; Retrospective Studies ; Saudi Arabia ; Tertiary Care Centers/economics ; Tertiary Care Centers/statistics & numerical data